Last reviewed · How we verify
NCT03336437
Estrogen and the Urogenital Microbiome in GSM
Phase 4 trial testing Estradiol vaginal ring in Menopause in 40 participants. Completed in 23 August 2019.
23 August 2019
Quick facts
| Lead sponsor | Oregon Health and Science University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 40 |
| Start date | 1 February 2018 |
| Primary completion | 23 August 2019 |
| Estimated completion | 23 August 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Estradiol vaginal ring — full drug profile →
- Placebo vaginal ring — full drug profile →
Conditions studied
- Menopause — all drugs for Menopause →
Sponsor
Oregon Health and Science University
Who can join
Adults 40 to 89, female only, with Menopause. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study of how local estrogen treatment affects the microbiome of the vagina and bladder in postmenopausal women experiencing symptoms as part of "Genitourinary Syndrome of Menopause." The goal is to understand more about the underlying microbial changes occurring in menopause and whether these are reversible with estrogen.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03336437
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Menopause
Currently open trials in the same condition.
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
- NCT07135232 — The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. · NA · recruiting
- NCT06975111 — Focusing on the Menopausal Transition to Improve Mid-Life Women's Health · Phase 2, PHASE3 · recruiting
- NCT07393672 — Effects of Hemp-Derived Cannabinoids on Menopause Symptoms · Phase 2 · recruiting
- NCT07412093 — The Effect of Progressive Relaxation Exercises and Planned Education on Menopausal Symptoms, Perceived Stress, and Anxie · NA · active not recruiting
Other Oregon Health and Science University trials
Trials by the same sponsor.
- NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
- NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
- NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
- NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
- NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03336437 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
- Last refreshed: 22 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03336437.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing